Publisher
About the Journal
Cancer Biotherapy and Radiopharmaceuticals is a leading peer-reviewed scientific journal published by SAGE Publications that focuses on innovative research in radioligand therapy and targeted radiopharmaceutical treatments for cancer and other diseases. Originally established as Antibody, Immunoconjugates, and Radiopharmaceuticals, the journal has evolved into an important platform for disseminating advances in nuclear medicine, oncology, radiochemistry, and molecular imaging. It is indexed in major international databases, including MEDLINE/PubMed, PubMed Central, EMBASE, Web of Science, and Scopus, reflecting its strong scientific visibility and impact.
The journal serves a multidisciplinary audience that includes oncologists, nuclear medicine physicians, radiologists, surgeons, pathologists, epidemiologists, pharmacologists, and cancer researchers. By integrating discoveries from clinical medicine, molecular biology, radiochemistry, and pharmaceutical sciences, the journal promotes the development and clinical translation of targeted radioligand therapies. Its publications contribute to improving precision medicine approaches and advancing patient-centered treatment strategies for cancer and other serious diseases.
Aim and Scope
The aim of Cancer Biotherapy and Radiopharmaceuticals is to advance scientific knowledge and clinical practice in the field of radioligand therapy and radiopharmaceutical medicine. The journal seeks to publish high-quality original research, reviews, and translational studies that explore innovative therapeutic approaches using radioactive compounds for diagnosis and treatment. It also encourages interdisciplinary collaboration to accelerate the development of effective, safe, and targeted therapies that improve patient outcomes.
The scope of the journal encompasses all aspects of radioligand therapy, including radiolabeled small molecules, peptides, antibodies, nanoparticles, DNA, RNA, and aptamers. It welcomes studies involving cancer treatment as well as emerging applications in non-oncological conditions such as infectious diseases, autoimmune disorders, and cardiovascular medicine. Research on immunotherapy, antibody-drug conjugates, cytokine therapy, gene therapy, and cell-based therapies is considered when these approaches are combined with or compared to radionuclide therapy. Through its broad coverage of radiopharmaceutical sciences, oncology, pharmacology, and molecular medicine, the journal supports the advancement of next-generation targeted therapeutic technologies.